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Some anti-inflammatory medications reduce alcohol consumption in rodent models.
Inhibition of phosphodiesterases (PDE) increases cAMP and reduces inflammatory
signaling. Rolipram, an inhibitor of PDE4, markedly reduced ethanol intake and preference
in mice and reduced ethanol seeking and consumption in alcohol-preferring fawn-hooded
rats (Hu et al., 2011; Wen et al., 2012). To determine if these effects were specific for
PDE4, we compared nine PDE inhibitors with different subtype selectivity: propentofylline
(nonspecific), vinpocetine (PDE1), olprinone, milrinone (PDE3), zaprinast (PDE5), rolipram,
mesopram, piclamilast, and CDP840 (PDE4). Alcohol intake was measured in C57BL/6J
male mice using 24-h two-bottle choice and two-bottle choice with limited (3-h) access
to alcohol. Only the selective PDE4 inhibitors reduced ethanol intake and preference in
the 24-h two-bottle choice test. For rolipram, piclamilast, and CDP840, this effect was
observed after the first 6 h but not after the next 18 h. Mesopram, however, produced
a long-lasting reduction of ethanol intake and preference. In the limited access test,
rolipram, piclamilast, and mesopram reduced ethanol consumption and total fluid intake
and did not change preference for ethanol, whereas CDP840 reduced both consumption
and preference without altering total fluid intake. Our results provide novel evidence for
a selective role of PDE4 in regulating ethanol drinking in mice. We suggest that inhibition
of PDE4 may be an unexplored target for medication development to reduce excessive
alcohol consumption.
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INTRODUCTION
Alcoholism is one of the most expensive (more than $185 bil-
lion/year in the US) and damaging chronic diseases (Bouchery
et al., 2011), yet there are only three FDA-approved drugs for
alcohol dependence (disulfiram, naltrexone, and acamprosate)
(Johnson et al., 2007). Disulfiram blocks the enzyme acetalde-
hyde dehydrogenase, preventing formation of acetic acid from
acetaldehyde (Heilig and Egli, 2006). Naltrexone blocks mu opi-
oid receptors thought to be responsible for the rewarding effects
of alcohol, thereby decreasing alcohol craving (Bouza et al.,
2004); however, naltrexone was only effective in a subpopula-
tion of recovering alcoholics. Acamprosate is thought to act by
decreasing glutamatergic activity, reducing the negative effects
associated with alcohol withdrawal. Treatment options are var-
ied but limited, and there is a high rate of relapse for all existing
treatments.
Current evidence suggests that brain immune or pro-
inflammatory signaling is linked to alcohol action (Crews, 2012;
Mayfield et al., 2013). Long-lasting increases in levels of several
cytokines in mouse brain, including monocyte chemoattractant
protein-1, MCP-1 (also known as chemokine C-C motif lig-
and 2, CCL2), were observed after pretreatment with high doses
of ethanol followed by injection of lipopolysaccharide (LPS)
Abbreviations: PDE, phosphodiesterases; cAMP, 3′,5′-cyclic adenosine
monophosphate; cGMP, 3′,5′-cyclic guanosine monophosphate.
(Qin et al., 2008). Interestingly, a similar increase in MCP-
1 (CCL2) was found in brains of human alcoholics (He and
Crews, 2008), and deletion of Ccl2 or its receptor decreased alco-
hol consumption in mice (Blednov et al., 2005). Knockout of
immune/inflammatory genes in mice, which were selected based
on meta-analyses of genes and functional pathways involved in
regulation of alcohol drinking in mice (Mulligan et al., 2006),
rats (Kimpel et al., 2007), or humans (Liu et al., 2006, 2007;
Flatscher-Bader et al., 2008), reduced ethanol intake and prefer-
ence, further supporting immune pathways in regulating alcohol-
mediated behaviors (Blednov et al., 2012). Our research suggests
that cytokines (perhaps via endotoxins) promote persistent and
excessive alcohol consumption, which may in turn promote fur-
ther inflammatory responses, producing a positive feedback loop
leading to excessive alcohol consumption (Blednov et al., 2011).
Furthermore, even a single injection of LPS induces a long-lasting
decrease in dopamine neuron firing in the ventral tegmental
area, suggesting that cytokine signaling can regulate reward cir-
cuitry (Blednov et al., 2011). It is also noteworthy that chronic
alcohol consumption and LPS treatment can produce similar
changes in mouse brain transcriptomes (Osterndorff-Kahanek
et al., 2013).
Phosphodiesterases (PDEs) are a superfamily of enzymes cat-
alyzing the hydrolysis of 3′,5′-cyclic adenosine monophosphate
(cAMP) and 3′,5′-cyclic guanosine monophosphate (cGMP) to
their inactive 5′-AMP and 5′-GMP forms, respectively. Increased
www.frontiersin.org May 2014 | Volume 8 | Article 129 | 1
Blednov et al. PDE4 inhibitors reduce ethanol intake
cAMP and/or cGMP, resulting from inhibition of PDE, reduces
inflammatory signaling (Page and Spina, 2011; Jin et al., 2012).
Cyclic nucleotides are known to play pivotal roles in a num-
ber of cellular functions, including immune and inflammatory
responses, cardiac activities, smooth muscle relaxation, depres-
sion and cognition. The anti-inflammatory actions of PDE
inhibitors are beneficial in treating chronic obstructive pul-
monary disease and asthma (Jin et al., 2012; Keravis and Lugnier,
2012). PDEs are encoded by 21 genes, grouped into 11 families,
according to their structural similarity. Each gene encodes mul-
tiple protein products generated by alternative splicing and/or
multiple promoters, resulting in more than 50 different PDE pro-
teins that may be produced in mammalian cells (Bender and
Beavo, 2006).
Rolipram, an inhibitor of PDE4, markedly reduced alcohol
intake and preference in mice (Hu et al., 2011) and reduced alco-
hol seeking and consumption in alcohol-preferring fawn-hooded
rats (Wen et al., 2012). Rolipram also reduced cocaine condi-
tioned place preference and self-administration (Knapp et al.,
1999; Thompson et al., 2004) and inhibited neuroimmune sig-
naling (Zhu et al., 2001). Rolipram and other PDE4 inhibitors
have been investigated as potential therapeutics in diverse CNS
disease models, including depression, anxiety, schizophrenia,
Parkinson’s, and Alzheimer’s disease (Halene and Siegel, 2007;
Kanes et al., 2007; Smith et al., 2009). In this study, we compared
the effects of various PDE inhibitors on alcohol consumption
and preference in mice. We studied nine PDE inhibitors with
different selectivity profiles (Shahid et al., 1991; Raeburn and
Karlsson, 1993; Ashton et al., 1994; Meskini et al., 1994; Sugioka
et al., 1994; Perry et al., 1998; Dinter et al., 2000): propento-
fylline (nonspecific); vinpocetine (PDE1); olprinone, milrinone
(PDE3); zaprinast (PDE5); rolipram, mesopram, piclamilast, and
CDP840 (PDE4) and examined their effects in two different
ethanol consumption tests.
MATERIALS AND METHODS
MICE
Male C57BL/6J mice were taken from a colony maintained at
The University of Texas at Austin (original breeders were pur-
chased from Jackson Laboratories, Bar Harbor, ME). Mice were
group-housed four or five to a cage. Food and water were avail-
able ad libitum. The vivarium was maintained on a 12:12 h
light/dark cycle with lights on at 7 a.m. The temperature and
humidity of the room were kept constant. Behavioral testing
began when the mice were at least 2 months old. All experi-
ments were conducted in isolated behavioral testing rooms in
the Animal Resources Center at The University of Texas with
reversed light cycle to avoid external distractions. Before begin-
ning experiments, mice were moved to their experimental room
and remained there for at least 2 weeks to adapt to the new
light cycle. All experiments were approved by the Institutional
Animal Care and Use Committee at The University of Texas at
Austin.
BASELINE DRINKING
In both ethanol consumption tests (described below), mice first
consumed 15% ethanol for at least 3 weeks. After this period,
ethanol consumption was measured for at least 4 days to ensure
stable consumption. The criterion for stable consumption was
similar values for days 1–2 and days 3–4. For the 24-h two-bottle
choice test, ethanol intake was then measured after saline injec-
tion for 2 days, and mice were grouped to provide similar levels
of ethanol intake and preference based on the first 6 h of con-
sumption during these 2 days. Ethanol and total fluid intake
were presented as g/kg/6 h. Measurements made after the next
18 h were presented as percent of corresponding control (values
obtained after the next 18 h during the first 2 days of saline injec-
tion). In the drinking in the dark (DID) test, mice were grouped
to provide similar levels of ethanol intake and preference based
on 3 h of consumption during the first 2 days of saline injections.
Ethanol and total fluid intake were presented as g/kg/3 h. From
day 3, mice were injected once daily with either saline or drugs
for up to 10 days, depending on the drug.
DRUG ADMINISTRATION
Propentofylline (5mg/kg), vinpocetine (10mg/kg), and piclami-
last (1mg/kg) were injected i.p. Olprinone (0.5mg/kg), milrinone
(0.5mg/kg), mesopram (5mg/kg), rolipram (1 and 5mg/kg),
CDP840 (10 and 25mg/kg), and zaprinast (10mg/kg) were
administered p.o. Drugs were purchased from Sigma-Aldrich (St.
Louis, MO) or Tocris Bioscience (Minneapolis, MN). All drugs
were freshly prepared as suspensions in saline with 4–5 drops of
Tween-80 and injected in a volume of 0.05ml/10 g of body weight
30–60min before drinking experiments. Saline containing 4–5
drops of Tween-80 was injected in the same volume for control
groups. Doses of drugs and routes of administration were based
on published data showing anti-inflammatory activity in vivo
(Yamada et al., 1998; Dinter et al., 2000; Prickaerts et al., 2004; Di
Paola et al., 2011; Xiao et al., 2011; Hotte et al., 2012). If the drug
was not effective within 4 days, a higher dose was then tested.
ETHANOL DRINKING—24-h TWO-BOTTLE CHOICE
The two-bottle choice protocol was carried out as previously
described (Blednov et al., 2001). Bottles were weighed twice
daily (see below). Food was available ad libitum, and mice were
weighed every 4 days beginning on day 1. Bottle positions were
changed daily to control for position preferences. Ethanol con-
sumption (g/kg body weight/time) was calculated for eachmouse.
Ethanol (15%) was used in all experiments, and mice had unlim-
ited access to one bottle of water. Ethanol intake was measured
6 h after the beginning of the drinking test and again after
the next 18 h. Measurements of ethanol intake, preference, and
total fluid intake were averaged over 2 days with different bot-
tle positions. Each point in the graphs (e.g., days 2, 4, 6, 8, 10)
represents the average of 2 days of measurement. For example,
day 2 is the average of days 1–2 and day 4 is the average of
days 3–4.
ETHANOL DRINKING—LIMITED ACCESS IN THE DARK PHASE
(TWO-BOTTLE CHOICE DID)
This was similar to the one-bottle DID test previously described
(Rhodes et al., 2005) except that two bottles containing either
15% ethanol or water were used (Blednov and Harris, 2008).
The ethanol and water bottles remained in place for 3 h.
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FIGURE 1 | PDE4 inhibitors reduce alcohol intake during the first 6 h of
the 24-h two-bottle choice paradigm. Ethanol consumption is presented as
g/kg/6 h: (A) Rolipram (D) Mesopram (G) CDP840 (J) Piclamilast. Preference
for ethanol: (B) Rolipram (E) Mesopram (H) CDP840 (K) Piclamilast. Total
fluid intake (g/kg/6 h): (C) Rolipram (F) Mesopram (I) CDP840 (L) Piclamilast.
Data were analyzed by Two-Way ANOVA with repeated measures followed
by Bonferroni’s test for multiple comparisons. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001 compared to control (n = 6 per group; EtOH = ethanol).
After their removal, mice had unlimited access to one bot-
tle of water. Bottle positions during 3-h access were changed
daily to control for potential side preferences. The ethanol and
water bottles were weighed before placing and after removal
from experimental cages. Drinking began 3 h after lights off
and continued for 3 h. Measurements of ethanol intake, pref-
erence, and total fluid intake were averaged over 2 days with
different bottle positions. Each point in the graphs (e.g.,
days 2, 4, 6, 8, 10) represents the average of 2 days of
measurement.
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FIGURE 2 | Effects of PDE4 inhibitors on alcohol intake during the next
18h of the 24-h two-bottle choice paradigm. Ethanol consumption is
presented as g/kg/18 h: (A) Rolipram (D)Mesopram (G) CDP840 (J)
Piclamilast. Preference for ethanol: (B)Rolipram (E)Mesopram (H)CDP840 (K)
Piclamilast. Total fluid intake (g/kg/18 h): (C)Rolipram (F)Mesopram (I)CDP840
(L) Piclamilast. Data were analyzed by Two-Way ANOVA with repeated
measures followed by Bonferroni’s test for multiple comparisons. ∗∗p < 0.01;
∗∗∗p < 0.001 compared to control (n = 6 per group; EtOH = ethanol).
STATISTICAL ANALYSIS
Data are reported as the mean ± s.e.m. The statistics soft-
ware program GraphPad Prism (Jandel Scientific, Costa Madre,
CA) was used throughout. Two-Way repeated measures ANOVA
with post-hoc Bonferroni corrections and Student’s t-tests were
performed.
RESULTS
TWO-BOTTLE CHOICE WITH CONTINUOUS ACCESS TO ALCOHOL
In the 24-h two-bottle choice continuous access test, all four
PDE4 inhibitors (rolipram, mesopram, piclamilast, CDP840)
reduced alcohol intake and preference after the first 6 h without
affecting total fluid intake (Figure 1; for complete statistical
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FIGURE 3 | PDE3 and PDE5 inhibitors do not alter alcohol intake
during the first 6 h of the 24-h two-bottle choice paradigm. Ethanol
consumption is presented as g/kg/6 h: (A) Milrinone (D) Olprinone (G)
Zaprinast. Preference for ethanol: (B) Milrinone (E) Olprinone (H)
Zaprinast. Total fluid intake (g/kg/6 h): (C) Milrinone (F) Olprinone (I)
Zaprinast. Data were analyzed by Two-Way ANOVA with repeated
measures followed by Bonferroni’s test for multiple comparisons (n = 6
per group; EtOH = ethanol).
analyses see Data Sheet 1). For rolipram, piclamilast, and
CDP840, this effect was not long lasting and was not observed
after the next 18 h of ethanol consumption (Figure 2; Data
Sheet 2). Mesopram, however, produced a long-lasting reduction
of ethanol intake and preference (measured after the next 18 h of
ethanol consumption) (Figures 2D,E; Data Sheet 2).
Inhibitors of other classes of PDEs (olprinone, milrinone,
zaprinast, propentofylline, and vinpocetine) had no effect on
ethanol consumption in the continuous access test at either time
point (Figures 3–5; Data Sheets 3, 4).
TWO-BOTTLE CHOICE WITH LIMITED ACCESS TO ALCOHOL
Because of the selective reduction by PDE4 inhibitors in con-
tinuous access drinking, only this subtype was studied in
the limited access test. In contrast to continuous access, roli-
pam (1mg/kg) did not change consumption in limited access
(Figures 6A–C; Data Sheet 5); however, 5mg/kg rolipram as well
as mesopram, piclamilast, and CDP840 strongly reduced alco-
hol intake (Figures 6A,D,G,J; Data Sheet 5). Of these inhibitors,
CDP840 also reduced alcohol preference (Figures 6H,I), whereas
rolipram, mesopram, and piclamilast failed to reduce alcohol
preference (Figures 6B,E,K) because they reduced total fluid
intake (Figures 6C,F,L; Data Sheet 5).
DISCUSSION
Rolipram was previously shown to reduce ethanol intake and
preference in mice (Hu et al., 2011) and rats (Wen et al., 2012)
in 24-h two-bottle choice tests, which is consistent with our
results in mice. We further demonstrate that other selective
PDE4 inhibitors (but not other classes of PDE inhibitors) reduce
intake and preference in the 24-h two-bottle choice paradigm.
Like rolipram, CDP840 and piclamilast transiently reduce intake,
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FIGURE 4 | PDE1 inhibitor vinpocetine and nonspecific inhibitor
propentofylline do not alter alcohol intake during the first 6 h of the 24-h
two-bottle choice paradigm. Ethanol consumption is presented as g/kg/6 h:
(A) Propentofylline (D) Vinpocetine. Preference for ethanol: (B)
Propentofylline (E) Vinpocetine. Total fluid intake (g/kg/6 h): (C)
Propentofylline (F) Vinpocetine. Data were analyzed by Two-Way ANOVA with
repeated measures followed by Bonferroni’s test for multiple comparisons
(n = 6 per group; EtOH = ethanol).
whereas mesopram produces long-lasting decreases. Hu et al.
(2011) did not report transient effects of rolipram, but they
injected it i.p. twice daily, whereas we used a once daily oral
administration. CDP840 also reduces ethanol intake and prefer-
ence in the limited access test, whereas the other PDE4 inhibitors
do not alter preference. Reduction of ethanol and total fluid
intake, without changes in preference, in the limited access test
may be due to the sedative activity of PDE4 inhibitors (Hu et al.,
2011). Any sedative effects would be likely to interfere with drink-
ing in this limited 3-h time period. However, mice in limited
access or “binge” models may also display a different sensitivity
to pharmacological intervention compared to mice undergoing
continuous access (Crabbe et al., 2011). Furthermore, these two
treatment paradigms induce different transcriptome signatures in
mouse brain (Osterndorff-Kahanek et al., 2013). Other classes of
inhibitors (nonspecific or PDE1, 3, or 5 inhibitors) had no effect
on alcohol consumption in the continuous access test. Similar to
our results with propentofylline, ibudilast (another nonspecific
PDE inhibitor) did not change alcohol intake in non-dependent
mice; however, ibudilast reduced drinking in alcohol-dependent
mice and in alcohol-preferring P andHAD1 rats (Bell et al., 2013).
Also, mice with genetic deletion of both adenylyl cyclase 1 (AC1)
and AC8 exhibited decreased ethanol consumption and enhanced
sensitivity to ethanol sedation (Maas et al., 2005). In contrast,
mice lacking AC5 showed increased ethanol consumption and
preference and reduced sensitivity to ethanol sedation (Kim et al.,
2011).
It is important to note that the PDE inhibitors which did not
alter alcohol consumption are nevertheless capable of exerting
other CNS-dependent effects on behavior and neurophysiology.
For example, olprinone and milrinone provided significant neu-
roprotection after cerebral ischemia/reperfusion injury in rats
(Saklani et al., 2010; Genovese et al., 2011). Zaprinast and other
PDE5 inhibitors improved memory (Prickaerts et al., 2004), and
propentofylline improved learning and memory deficits induced
by beta-amyloid protein (Yamada et al., 1998). Also, vinpoce-
tine ameliorated hyperactivity in a mouse model of fetal alcohol
spectrum disorder (Nunes et al., 2011).
Despite a long history of availability (since the late 1980’s),
PDE inhibitors are of limited clinical use because of lack of
efficacy and/or gastroenterological side effects such as nausea
and vomiting (Giembycz, 2008). One approach to mitigate the
adverse effects is seeking agents with selectivity for PDE4 iso-
forms devoid of these effects. PDE4 isoenzymes are encoded by
four genes (A, B, C, D), and it is believed that inhibition of
PDE4D promotes emesis. Selective inhibition of PDE4A and/or
PDE4B in pro-inflammatory and immune cells is believed to
produce desired anti-inflammatory effects (Giembycz, 2008; Jin
et al., 2012). PDE4B is of particular interest because it is local-
ized in brain reward pathways (Cherry and Davis, 1999), and its
expression is upregulated in mice with a genetic predisposition
for high alcohol consumption (Mulligan et al., 2006). Rolipram
inhibits PDE4 catalytic activity with micromolar potency but also
binds to a high affinity (nanomolar) site on PDE4 (Schneider
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FIGURE 5 | PDE1,3,5 and nonspecific inhibitors do not alter alcohol
intake during the last 18h of the 24-h two-bottle choice
paradigm. Ethanol consumption is presented as g/kg/18 h: (A)
Milrinone (D) Olprinone (G) Zaprinast (J) Propentofylline (M)
Vinpocetine. Preference for ethanol: (B) Milrinone (E) Olprinone (H)
Zaprinast (K) Propentofylline (N) Vinpocetine. Total fluid intake
(g/kg/18 h): (C) Milrinone (F) Olprinone (I) Zaprinast (L) Propentofylline
(O) Vinpocetine. Data were analyzed by Two-Way ANOVA with
repeated measures followed by Bonferroni’s test for multiple
comparisons (n = 6 per group; EtOH = ethanol).
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FIGURE 6 | Effects of PDE4 inhibitors on alcohol intake during a
limited access (3-h) two-bottle choice Drinking in the Dark test.
Ethanol consumption is presented as g/kg/3 h: (A) Rolipram (D)
Mesopram (G) CDP840 (J) Piclamilast. Preference for ethanol: (B)
Rolipram (E) Mesopram (H) CDP840 (K) Piclamilast. Total fluid
intake (g/kg/3 h): (C) Rolipram (F) Mesopram (I) CDP840 (L)
Piclamilast. Data were analyzed by Two-Way ANOVA with repeated
measures followed by Bonferroni’s test for multiple comparisons.
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001 compared to control (n = 6 per
group; EtOH = ethanol).
et al., 1986). Duplantier et al. (1996) noted a relationship between
the high affinity site (in rats) and emesis (in ferrets), and there
is a correlation between high affinity binding of denbufylline,
rolipram, piclamilast, CDP840, and KF19514 and their emetic
activity in the house musk shrew (Hirose et al., 2007). Thus,
inhibitors with lower selectivity for PDE4D and lower binding
to the high affinity site may reduce the side effects of these
drugs.
Given the proposed link between neuroimmune signaling and
alcohol consumption and dependence (Harris and Blednov, 2013;
Mayfield et al., 2013), PDE inhibitors could potentially decrease
alcohol consumption by inhibiting inflammatory signaling.
Frontiers in Neuroscience | Neuropharmacology May 2014 | Volume 8 | Article 129 | 8
Blednov et al. PDE4 inhibitors reduce ethanol intake
Indeed, rolipram dose-dependently reduced LPS-induced pro-
duction of TNFα in rat brain and microglia (Buttini et al., 1997;
Yoshikawa et al., 1999). Furthermore, LPS, pro-inflammatory
cytokines, and ethanol all increased the activity of PDE4 in sev-
eral types of cells (microglia, astrocytes, bronchial epithelial), and
these effects were reversed by rolipram (Buttini et al., 1997; Forget
et al., 2003; Ghosh et al., 2012).
Our work represents the first comparison of different classes of
PDE inhibitors in different ethanol drinking tests in mice with a
genetic predisposition for high alcohol consumption. We provide
strong evidence for a selective role of PDE4 inhibitors in reducing
alcohol consumption and preference. PDE4 inhibitors have also
been investigated in animal models of other CNS disorders, and
the availability of more selective isoforms devoid of side effects
may prove beneficial in the treatment of alcohol abuse and other
inflammatory diseases.
In addition to behavioral evidence for specific PDEs in alco-
hol drinking in rodents, there is evidence for altered expression of
PDE genes in mice following chronic ethanol. For example, Pde10
and Pde1b were upregulated in mouse prefrontal cortex after
chronic ethanol intake (Osterndorff-Kahanek et al., 2013), and
Pde4bwas upregulated while Pde10awas downregulated in brains
of mice showing a genetic predisposition to high alcohol con-
sumption (Mulligan et al., 2006). Furthermore, the Collaborative
Study on the Genetics of Alcoholism (COGA) identified a can-
didate single nucleotide polymorphism near PDE11A based on
differing allele frequencies between alcohol-dependent and con-
trol individuals (Johnson et al., 2006). While both mouse and
human studies nominate PDE genes, confirmation using multi-
ple datasets combined with behavioral validation will ultimately
be important to link them to addiction vulnerability.
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